40
Participants
Start Date
September 25, 2020
Primary Completion Date
October 27, 2021
Study Completion Date
February 28, 2026
Pexidartinib
400 mg twice daily for a total daily dose of 800 mg (each capsule contains 200 mg of pexidartinib for oral administration)
Beijing Ji Shui Tan Hospital, Beijing
Peking University Cancer Hospital, Beijing
The First Affiliated Hospital, Sun Yat-sen University, Guangzhou
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou
Zhejiang Cancer Hospital, Hangzhou
Fudan University Shanghai Cancer Center, Shanghai
Shanghai General Hospital, Shanghai
National Taiwan University Hospital, Taipei
Taipei Veterans General Hospital, Taipei
Lead Sponsor
Daiichi Sankyo Co., Ltd.
INDUSTRY